Galmed Pharmaceuticals Ltd
NASDAQ:GLMD

Watchlist Manager
Galmed Pharmaceuticals Ltd Logo
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Watchlist
Price: 0.8223 USD -2.4% Market Closed
Market Cap: 4.5m USD

Galmed Pharmaceuticals Ltd
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Galmed Pharmaceuticals Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Cash from Operating Activities
-$6.3m
CAGR 3-Years
33%
CAGR 5-Years
22%
CAGR 10-Years
3%
Kamada Ltd
NASDAQ:KMDA
Cash from Operating Activities
$29m
CAGR 3-Years
20%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Cash from Operating Activities
-$137.7m
CAGR 3-Years
-17%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Cash from Operating Activities
-$7m
CAGR 3-Years
19%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Cash from Operating Activities
-$19.6m
CAGR 3-Years
18%
CAGR 5-Years
5%
CAGR 10-Years
1%
M
Matricelf Ltd
TASE:MTLF
Cash from Operating Activities
-₪11.8m
CAGR 3-Years
-21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Galmed Pharmaceuticals Ltd
Glance View

Market Cap
4.5m USD
Industry
Biotechnology

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

GLMD Intrinsic Value
3.7672 USD
Undervaluation 78%
Intrinsic Value
Price

See Also

What is Galmed Pharmaceuticals Ltd's Cash from Operating Activities?
Cash from Operating Activities
-6.3m USD

Based on the financial report for Sep 30, 2025, Galmed Pharmaceuticals Ltd's Cash from Operating Activities amounts to -6.3m USD.

What is Galmed Pharmaceuticals Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
3%

Over the last year, the Cash from Operating Activities growth was -32%. The average annual Cash from Operating Activities growth rates for Galmed Pharmaceuticals Ltd have been 33% over the past three years , 22% over the past five years , and 3% over the past ten years .

Back to Top